CEO Executive AssistantThe Strategic Imperative of Pricing and Market Access Operations
In the pharmaceutical industry, a breakthrough molecule with poor pricing and market access execution is a commercial failure. The science and the operations are inseparable. For pharma CEOs, this means that pricing strategy and market access are not functions to be delegated entirely to commercial teams. They require direct executive oversight, cross-functional integration, and operational systems capable of managing complexity across markets, payers, and policy environments.
The stakes have never been higher. Government scrutiny of drug pricing has intensified across virtually every major market. Payer sophistication has grown substantially, with evidence requirements that were once reserved for premium products now applied broadly. And the window between regulatory approval and first commercial sale has compressed, leaving less time to build the market access infrastructure that determines whether a product achieves its revenue potential.
Pharma CEOs who build world-class pricing and market access operations create durable competitive advantages that extend far beyond any single product launch.
Integrating Pricing Strategy into the Development Process
Early-Phase Value Architecture
The most common market access failure is treating pricing strategy as a launch-phase activity. By the time a product reaches Phase III, many of the clinical decisions that determine payer acceptance have already been made. Comparator selection, trial endpoints, patient population definitions, and outcome measures all have profound implications for the value story a company can tell to payers.
CEOs should require that every development program include a market access team member from Phase II onward. This team member’s role is to ensure that clinical development decisions reflect the evidentiary standards that payers will apply when the product seeks formulary access. The cost of incorporating this perspective early is minimal compared to the cost of repositioning a market access strategy after Phase III data has been locked.
Value Dossier Development
A comprehensive global value dossier is the foundational document for market access negotiations. It should synthesize clinical evidence, health economic data, comparative effectiveness analysis, and patient-reported outcomes into a coherent value narrative that is adaptable for different market contexts.
The value dossier is a living document, not a static submission. As post-approval real-world evidence accumulates, the dossier should be updated to reflect new data that strengthens the product’s value position. CEOs should ensure that market access teams have the budget and mandate to develop and maintain value dossiers throughout the product lifecycle, not just at launch.
Pricing Architecture and Decision Governance
Global Pricing Principles
Pharmaceutical pricing operates in a complex global interdependency where the price set in one market can create reference pricing pressure in others. CEOs must establish clear global pricing principles that guide market-level decisions and prevent short-term local deals from creating long-term global pricing erosion.
These principles should address the minimum acceptable net price floor across markets, the approach to managing international reference pricing relationships, the conditions under which confidential discounts or managed entry agreements are acceptable, and the process for approving exceptions to standard pricing policy. Without these principles, pricing decisions made under commercial pressure in individual markets can collectively undermine the product’s global value position.
Pricing Committee Governance
Every pharma organization with a significant commercial portfolio should have a pricing committee that governs major pricing decisions with appropriate executive oversight. The pricing committee should include the CEO or a direct delegate, the chief commercial officer, the chief medical officer, the head of market access, the chief financial officer, and regional commercial leaders for major markets.
The committee should meet regularly to review pricing decisions that exceed defined thresholds and to monitor the performance of existing pricing strategies. Between meetings, a clear delegation of authority framework should specify which pricing decisions can be made at each organizational level without committee approval. For broader commercial operations context, see the pharma commercial excellence framework.
Payer Engagement Operations
Mapping the Payer Landscape
Effective payer engagement begins with a comprehensive map of the payer landscape in each target market. This map should identify the key decision-makers for formulary access, the decision process and timeline, the evidence requirements and value thresholds applied by each payer, and the reimbursement mechanisms through which the product would be paid.
In markets with multiple payers, such as the United States, this mapping exercise is extensive but essential. The operational reality is that a product may face 50 or more significant payer organizations, each with different formulary processes, evidence preferences, and contracting requirements. CEOs should ensure that market access teams have the resources to develop and maintain current intelligence on all significant payers in each major market.
Value-Based Contracting Capabilities
Value-based contracts, also known as outcomes-based agreements, link reimbursement levels to demonstrated clinical outcomes in real-world practice. They are increasingly demanded by sophisticated payers as a mechanism for managing the risk of paying for products that may not perform as well in real-world populations as in controlled clinical trials.
Building the operational capability to execute value-based contracts requires investment in several areas: data infrastructure that can capture and report real-world outcomes, legal and compliance frameworks that govern data sharing and contract terms, analytics capabilities that can identify when performance thresholds have been met, and contracting teams with the expertise to negotiate complex multi-year agreements. This is not a capability that can be assembled quickly; CEOs should begin building it early in the product development lifecycle for any asset where value-based contracting is a likely payer demand.
Managed Entry Agreements
In markets with centralized health technology assessment processes, such as the United Kingdom, Germany, France, and increasingly others, managed entry agreements provide a mechanism for achieving early access while post-approval evidence is generated. These agreements typically involve a combination of price discounts, patient access programs, and evidence generation commitments.
CEOs must understand that managed entry agreements are not simply pricing concessions. They are complex operational commitments that require sustained execution over multi-year periods. The organization must be capable of generating the agreed evidence, reporting it accurately, and managing the financial reconciliation that often accompanies these agreements. Underfunding managed entry agreement execution is a common mistake that can result in both financial penalties and reputational damage with payers.
Health Technology Assessment Navigation
Understanding HTA Requirements by Market
Health technology assessment bodies such as NICE in the United Kingdom, IQWiG in Germany, HAS in France, and PBAC in Australia have distinct methodological preferences, evidence standards, and decision-making processes. A market access strategy that treats all HTA bodies as equivalent will systematically underperform.
CEOs should ensure that their market access function maintains deep expertise in each major HTA market, either through internal staff or external advisory relationships. This expertise should inform not only submission strategies but also upstream clinical development decisions about trial design, comparator selection, and health economic modeling approaches.
Managing HTA Timelines and Reimbursement Gaps
The gap between regulatory approval and reimbursement approval in major markets has grown significantly, creating a period during which patients may have theoretical access to a product but lack practical access due to the absence of coverage. In some markets, this gap can extend to 12 to 18 months or more.
CEOs should track HTA timelines as a key commercial performance indicator and hold market access leaders accountable for minimizing reimbursement gaps through proactive engagement with HTA bodies, early scientific advice processes, and robust submission quality. The cost of delayed reimbursement is not only lost revenue; it also delays the accumulation of real-world evidence that can support subsequent payer negotiations.
Pricing Transparency and Policy Navigation
Managing the Policy Environment
The political and policy environment around pharmaceutical pricing has become one of the most significant operational variables for pharma CEOs. In the United States, the Inflation Reduction Act’s drug price negotiation provisions represent a fundamental change to the pricing environment for Medicare-covered products. In Europe, the Joint Clinical Assessment process is creating new cross-border evidence standards.
CEOs need dedicated policy intelligence capabilities that monitor legislative and regulatory developments across major markets, model the potential commercial impact of proposed policy changes, and develop operational responses before policies are finalized. Reactive policy engagement is significantly less effective than proactive engagement that helps shape the evidence standards and implementation details of pricing regulations.
Transparency and Public Narrative
The public narrative around pharmaceutical pricing has significant implications for a company’s regulatory relationships, legislative environment, and employer brand. CEOs have an opportunity to lead on transparency by clearly communicating the investments and risks involved in drug development, the value that innovative products create for patients and health systems, and the company’s approach to ensuring access for patients who cannot afford market prices.
This public narrative is not separate from pricing operations; it is an integral part of managing the political and policy environment within which pricing decisions are made. According to McKinsey’s analysis of pharmaceutical commercial models, companies that lead on transparency and value demonstration consistently outperform peers in payer negotiations and policy environments.
Operational Excellence in Market Access Teams
Building World-Class Market Access Capabilities
Market access is increasingly a source of competitive differentiation rather than a back-office function. The best market access teams combine deep health economic expertise, payer relationship knowledge, regulatory intelligence, and commercial acumen. Building these capabilities requires investment in talent acquisition, professional development, and knowledge management systems.
CEOs should treat market access talent as a strategic asset. The cost of losing a senior market access professional with deep relationships in a major market or deep expertise in a critical HTA process can be measured in months of delayed reimbursement and millions of dollars in foregone revenue.
Integrating Market Access with Commercial Operations
Market access and commercial operations must be tightly integrated to ensure that pricing decisions, formulary positions, and managed care contracts translate effectively into sales force execution. Nothing undermines a carefully constructed payer strategy faster than a sales force that misrepresents formulary status, makes unauthorized pricing commitments, or fails to communicate coverage limitations accurately to prescribers.
CEOs should require that market access and commercial operations leaders participate in joint business planning processes, share a common data infrastructure, and align on the metrics that define market access success for each product. The pharma operations checklist provides a structured framework for ensuring this cross-functional alignment is built into standard operating procedures.
Conclusion
Pricing and market access operations are among the most complex and consequential functions in the pharmaceutical industry. CEOs who invest in building world-class capabilities in this domain, through early integration in development, rigorous governance, sophisticated payer engagement, and proactive policy management, create organizations that can convert scientific innovation into sustainable commercial success.
The window for building these capabilities is the development phase, not the launch phase. CEOs who understand this and act accordingly will consistently outperform competitors who treat market access as a late-stage commercial activity.
Related Reading
For further context, explore Pharma CEO Business Operations Checklist and Allergy Portfolio Pharma CEO Business Operations: Strategic Execution Guide.